FIELD: medicine.
SUBSTANCE: group of inventions refers to cancer treatment, in which somatostatin receptors are expressed. Invention discloses conjugates, particularly
.
Also disclosed is a particle comprising a conjugate and at least one polymer matrix, a pharmaceutical composition comprising a conjugate or particle and at least one pharmaceutically acceptable excipient, method of treating cancer in an individual, a method of inhibiting tumour growth rate, tumour size or tumour volume, a method of delivering tumour mesanthin.
EFFECT: group of inventions provides improved temporary-spatial delivery of the active agent and improved biodistribution.
16 cl, 8 dwg, 16 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG BILIGAND CONJUGATE AND USE THEREOF | 2020 |
|
RU2820346C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| PRODRUG CONTAINING A SELF-CLEAVABLE LINKER | 2018 |
|
RU2798085C2 |
| PRODRUG CONTAINING SELF-CLEAVABLE LINKER | 2014 |
|
RU2676324C2 |
| CONJUGATES OF LIGAND AND DRUGS | 2006 |
|
RU2470668C2 |
| ANTIBODY-DRUG CONJUGATE HAVING AN ACID SELF-STABILIZING BINDING SITE | 2018 |
|
RU2793125C2 |
| IMPROVED POLYETHYLENIMINE POLYETHYLENE GLYCOL VECTORS | 2015 |
|
RU2771104C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| CONJUGATES FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO, CONTAINING BONDS SENSITIVE TO ENZYMATIC DEGRADATION | 2011 |
|
RU2619453C2 |
